Screener
Halozyme Therapeutics HALO Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 82.4%-1.8pp | 82.8%-0.7pp | 83.6%-0.7pp | 84.5%+2.5pp | 84.2%+4.2pp | |
| Efficiency | ||||||
| Asset turnover | 0.7×+0.1× | 0.6×+0.1× | 0.6×+0.1× | 0.6×+0.1× | 0.6×+0.1× | |
| Liquidity | ||||||
| Current ratio | 2.7×-5.7× | 2.8×-5.6× | 4.7×-3.1× | 1.6×-8.8× | 8.4×+1.0× | |
| Leverage | ||||||
| Debt-to-equity | 15.2×+10.6× | 9.9×+6.7× | 44.6×+40.4× | 3.1×-0.3× | 4.6×-0.7× | |
| Per Share | ||||||
| Book value per share | $1.18-55.8% | $1.79-53.1% | $0.39-86.0% | $4.12+18.4% | $2.68+19.7% | |
| Valuation | ||||||
| Market capitalization | $9.91B+36.0% | $7.66B-2.9% | $7.91B+30.1% | $8.58B+17.9% | $6.64B-0.1% | |
| Price / sales | 6×-0.2× | 5.1×-2.2× | 5.7×-0.3× | 6.9×-0.8× | 5.6×-2.0× | |
| Price / book | 69.1×+47.2× | 34.9×+18.5× | 162.1×+145× | 17×+1.0× | 20×-3.0× |
FAQ
- What are Halozyme Therapeutics's profit margins?
- Halozyme Therapeutics (HALO) runs a 82.4% gross margin and a 59.3% operating margin, with a 47.9% net margin.
- Where do Halozyme Therapeutics's ratios come from?
- Every ratio is computed from Halozyme Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
